OXACILLIN for Injection, USP Recall Information Customer Notification / Recall Communication Letter – OXACILLIN for Injection, USP (Lot OXT512. August 17, 2016) Customer Recall Return Response Form – OXACILLIN for Injection, USP (Lot OXT512. August 17, 2016) sagentadmin | Aug 17, 2016 | Sagent | « OXACILLIN for Injection, USP Recall Information Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction »
